Market Signal Briefing

A startup backed by Nvidia plans to begin testing Bitcoin mining in space later this year, marking one of the most unusual attempts yet to move crypto infrastructure beyond Earth.

Starcloud, a space infrastructure startup founded in 2024, says it intends to place Bitcoin mining hardware aboard a spacecraft scheduled for launch later this year. If successful, the company believes orbital computing could eventually become a major industry.

Startup CEO Philip Johnston wrote on social media X that Starcloud aims to become the first company to mine Bitcoin outside Earth. He previously discussed the concept in an interview with HyperChange.

The idea reflects a broader push among tech companies to explore space-based data centers as global demand for computing power grows.

Why the company believes space mining could workAccording to Johnston, launching specialized Bitcoin mining machines into orbit could be economically attractive because of the type of hardware involved.

Bitcoin mining relies on ASIC chips, which are purpose-built processors designed for hashing operations. Johnston argues that these chips provide significantly more computing power per unit of electricity than general-purpose AI hardware.

“A GPU is about 30 times more expensive per kilowatt than an ASIC,” Johnston explained. “A B200 chip with a power draw of 1 kilowatt costs around $30,000. An ASIC with the same power draw costs about $1,000.”

That difference becomes important in space, where launching equipment is extremely expensive. The lower cost per kilowatt could make ASIC-based systems more practical for orbital computing.

Johnston also believes the long-term economics of mining on Earth are becoming less attractive.

Bitcoin mining currently consumes roughly 20 gigawatts of electricity worldwide. Johnston argues that as energy constraints grow, the industry could eventually look toward solar-powered infrastructure in orbit.

He predicts that Bitcoin mining in space could evolve into a “massive industry” over time.

The long-term vision of orbital data centersStarcloud’s broader goal goes far beyond cryptocurrency.

The company was founded to build space-based data centers designed to meet the rapidly growing energy needs of artificial intelligence and high-performance computing.

In November 2025, Starcloud launched a satellite carrying an Nvidia H100 GPU into orbit, marking the first time such a powerful AI chip had operated in space.

The company’s long-term plan envisions an orbital infrastructure of roughly 88,000 satellites powered primarily by solar energy. In theory, this network could support both AI computing and specialized workloads like Bitcoin mining.

Could Bitcoin eventually be mined beyond Earth?The concept of moving crypto infrastructure into space has also sparked discussion about interplanetary transactions.

Technologists Jose E. Puente and Carlos Puente suggested last September that Bitcoin transactions could theoretically reach Mars in under three minutes using optical communication links such as those developed by NASA or Starlink.

Their proposed system would rely on a network of satellites, antennas, and possibly a lunar relay node to transmit transactions across planetary distances.

However, the researchers argue that mining Bitcoin directly on Mars would be impractical because of the long communication delays between planets.

Legal and technical questions remainDespite the excitement surrounding orbital mining, the idea also raises complex legal and technical issues.

Under the 1967 United Nations Outer Space Treaty, satellites remain under the jurisdiction of the country in which they are registered. However, the treaty does not clearly define how cryptocurrency mined in space would be taxed or regulated.

There are also technical challenges. Low Earth orbit satellites can only communicate with ground stations during short windows as they pass overhead. This could create interruptions in transmitting newly mined blocks to the Bitcoin network.

Whether these limitations would significantly affect profitability remains unclear.

Meanwhile miners on Earth face pressureWhile experimental space projects gain attention, traditional Bitcoin miners continue operating under difficult market conditions.

Bitcoin’s price has fallen nearly 48% from its all-time high of $126,080 reached in October. At the same time, mining difficulty recently declined about 7% from record levels, offering some relief to operators.

For now, mining remains firmly Earth-bound.

But if Starcloud’s experiment succeeds, the next frontier for Bitcoin may not be another country or continent, it could be orbit.

BitMine Immersion Technologies, the top Ethereum treasury firm by total holdings, announced Monday that it added nearly 61,000 more ETH over the last week—right as the asset reclaimed a price of $2,000 per coin after sitting below that mark for the entire weekend.

The publicly traded firm now holds 4,534,563 ETH after adding 60,976 ETH—about $123 million worth—over the last week. At a current price of $2,015 per coin, that puts BitMine's Ethereum treasury at a value of approximately $9.14 billion. The company also holds $1.2 billion in cash, it said Monday, along with about $13.4 million worth of Bitcoin.

Ethereum is up nearly 5% over the last week, though it's been a volatile one. The second-largest cryptocurrency by market cap jumped to a price of $2,179 on Wednesday alongside a broader crypto market rebound, but then gave up those gains and fell below the $2,000 mark as of Friday. It remained below that level until early hours Monday.

"Ethereum prices showed resilience this week, in the face of rising war concerns and surging oil prices," said BitMine Chairman Tom Lee, in a statement. "We continue to believe that crypto prices are in the late/final stages of the 'mini-crypto winter.'"

Even with the uptick over the last week, Ethereum traders remain bearish on the coin's short-term prospects. Traders on Myriad, a prediction market platform operated by Decrypt's parent company Dastan, currently see ETH's next stop as $1,500 rather than $3,000, giving the lower mark a 67% likelihood.

BitMine Immersion Technologies is the second-largest overall cryptocurrency treasury firm behind Strategy, which pioneered the model when it began buying Bitcoin in 2020 and now holds nearly $51 billion worth of the leading digital asset.

However, both firms—and effectively all other prominent crypto treasury firms—are now deeply underwater on their holdings due to crypto prices plunging in recent months. BitMine's unrealized loss on its ETH holdings sits near $7.8 billon, based on cost basis data and estimates from analytics website DropsTab, though it currently lacks data from the firm's last two weeks of ETH buys.

The price of Ethereum has fallen 59% since setting a new all-time high mark of $4,946 last August. However, after months of losses, ETH is nearly even over the last 30 days per data from CoinGecko.

BitMine has staked about $6 billion worth of its ETH holdings to earn yield from the Ethereum network, and plans to fully stake all of its holdings with the upcoming launch of its own Made in American Validator Network (aka MAVAN). Once fully staked, the firm expects to earn approximately $259 million a year in yield based on current rates.

BitMine (BMNR) stock is up more than 3% as of this writing, shortly after the opening bell, trading at $19.49. The stock has fallen almost 10% over the last month, despite ETH being roughly even over the same span. Major stock indices are down early Monday as traders weigh the impact of surging oil prices following the U.S. and Israeli bombings on Iran.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Bitcoin price has slipped below $70,000 as oil prices surge more than 60% this year amid rising tensions around the Strait of Hormuz, adding macro pressure to risk assets.

Summary

Bitcoin trades near $69,984 after falling 3.8% in the past 24 hours, though it remains up about 7.8% over the week. Oil prices have surged more than 60% this year as tensions around the Strait of Hormuz raise concerns about supply disruptions and inflation. Rising short-term volatility suggests the Bitcoin market is entering a repositioning phase that could lead to a larger move in either direction. Bitcoin (BTC) was trading at $69,984 at press time, down 3.8% over the past 24 hours as risk sentiment across financial markets softened. The pullback comes after a volatile week. 

Despite the recent drop, Bitcoin is still up roughly 7.8% for the week and has fluctuated between $63,176 and $73,669 over the last seven days. However, the cryptocurrency is still trading about 44% below its all-time high of $126,080 in October 2025. 

The most recent price fluctuations have increased activity in the derivatives market. Open interest rose 1.24% to $44.39 billion, while trading volume increased 57.9% to $67.26 billion, according to CoinGlass data.

The rise indicates that as global market uncertainty increases, traders are actively re-positioning their portfolios.

Oil surge raises macro pressure A report published on March 9 by CryptoQuant analysts points to rising geopolitical tensions around the Strait of Hormuz as a potential headwind for Bitcoin and other risk assets.

Due to growing worries about supply disruptions, oil prices have risen by more than 60% since the beginning of the year. The Strait of Hormuz is a vital part of the world’s energy markets, accounting for about 20% of daily oil exports and nearly 35% of oil transported by sea.

If this restricted shipping route is disrupted, energy costs could increase significantly. An increase in oil prices, according to analysts, could worsen inflation and put pressure on financial markets, which are already susceptible to supply disruptions.

This kind of macro-environment has historically been difficult for Bitcoin. Sharp increases in oil prices often coincide with later stages of market cycles, when risk appetite starts to decline. Exposure to speculative assets like cryptocurrencies may be discouraged by increased geopolitical tension.

Volatility signals market re-positioning Bitcoin’s volatility structure has changed noticeably in recent months, according to a separate analysis using data from the Binance BTC Volatility & Range Engine. There have been significant short-term fluctuations.

After rising above 1.5 in February before declining once more, the 7-day volatility measure was recently close to 0.72. These kinds of abrupt spikes typically occur during times of market stress and are frequently connected to significant portfolio adjustments or derivatives liquidations.

Longer-term volatility, however, has stayed relatively stable. The 30-day volatility sits around 0.50, while the 90-day measure is close to 0.57. This suggests that although short-term price swings have increased, the overall market structure has not entered an extreme volatility phase.

The Average True Range indicator currently stands near 0.054, pointing to a moderate trading range compared with past periods of intense market activity.

Taken together, the data suggest Bitcoin is going through a repositioning phase after its earlier rally. Buyers and sellers are still competing for control in the short term, which explains the recent spikes in volatility.

At the same time, longer-term volatility remains contained, indicating that the market has not yet entered a full panic or euphoria phase.

XRP price may be approaching a critical moment after weeks of downside pressure. The token has remained down roughly 8% over the past 30 days, showing that the broader structure is still bearish.

However, a historical chart formation that previously triggered a rebound has appeared again. This time, the signal is accompanied by a sharp collapse in coin distribution and rising holder conviction, raising the possibility that XRP could attempt a trend reversal if key levels break.

Historical Divergence Returns as XRP Prints the Same Bounce SetupThe current setup begins with a bullish divergence on the Relative Strength Index (RSI). RSI is a momentum indicator that measures the speed and strength of price movements. When price falls, but RSI rises, it often signals that selling momentum is weakening.

Between February 11 and March 8, XRP’s price formed a lower low, while RSI formed a higher low. This is a pattern that often appears near potential trend reversal zones, assuming the fact that the broader XRP price trend still leans bearish.

Note: While this divergence pattern conceptually hints at a reversal, we would be using the word ‘rebound’ interchangeably, considering the bearish market sentiments.

Interestingly, XRP printed a nearly identical divergence earlier. Between February 12 and February 24, the price also made a lower low while RSI formed a higher low. Shortly after that signal appeared, XRP rallied about 14%, confirming the divergence’s effectiveness.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Historical XRP Pattern: TradingViewHowever, technical patterns alone rarely drive price moves. The strength of the current divergence becomes clearer when examining on-chain distribution activity.

XRP Distribution Activity Collapses as Selling Sentiment FadesOne of the most important supporting signals comes from the Spent Coins age band data. This metric tracks how many tokens move on-chain each day, often signaling potential distribution.

During the earlier February divergence, spent coins declined from 75.58 million XRP to nearly 43 million XRP, representing a 43% drop in distribution activity.

Spent Coins Movement: SantimentThe current divergence shows a far sharper change. On March 7, spent coins surged to 122 million XRP, signaling heavy coin movement. But by March 8, the figure collapsed to 19.77 million XRP, marking an over 80% drop in distribution activity.

XRP Coin Activity: SantimentSuch a steep decline in this bearish metric suggests that selling activity may have dried up rapidly after the divergence formed. With fewer coins moving on-chain, the market may be entering a period where holders prefer holding rather than distributing tokens.

That behavior becomes even more visible when looking at long-term holder accumulation.

Hodler Accumulation and Derivatives Strengthen the Reversal SetupAnother key indicator is Hodler Net Position Change, which tracks how much supply long-term holders accumulate or distribute over a 30-day period.

During the February divergence, this metric showed only modest growth. On February 12, the net position change stood near 126.8 million XRP, rising slightly to about 149.3 million XRP by February 24—an increase of roughly 17%.

The current divergence shows stronger conviction. By March 3, the metric had dropped sharply to around 41.4 million XRP, but it rebounded quickly to 211.6 million XRP by March 8 when the divergence appeared.

Compared with the 149 million XRP level seen during the previous rebound signal (February 14), the current figure represents roughly 42% higher accumulation, indicating stronger holder conviction behind the potential reversal setup.

Hodler Net Position Change: GlassnodeBut spot market behavior is only part of the story. Derivatives positioning suggests another possible catalyst.

Derivatives data shows that short positions dominate XRP’s leverage structure. Liquidation data, per the XRP/USDT pair on Binance alone, indicates that roughly $110.8 million in short leverage sits above current prices, compared with only $42.1 million in long leverage. In other words, short exposure is about 163% larger than long exposure.

More importantly, over 50% of these short liquidations cluster around the $1.39 level.

XRP Liquidation Map: CoinglassIf XRP pushes toward $1.40 (a round figure), a large portion of these short positions could be forced to close. This type of forced buying, known as a short squeeze, often accelerates upward momentum.

XRP Price Levels That Could Confirm a ReversalFrom a technical perspective, XRP must first overcome $1.40, the level where large clusters of short liquidations sit. A break above that zone could trigger further upside toward $1.54, representing roughly 10% upside from current levels.

If momentum strengthens further, XRP could target $1.61, marking a potential 20% rally from the current range. The 10% to 20% rally range aligns with the bullish push seen during the historical divergence pattern from earlier.

However, downside risks remain. If XRP drops below $1.32, the current divergence structure would weaken. A deeper move under $1.27 would invalidate the bullish setup entirely and reinforce the broader bearish trend.

XRP Price Analysis: TradingViewFor now, XRP sits at a technical crossroads. A historical divergence has returned, distribution activity has dropped sharply, and holder accumulation has strengthened. Whether these signals translate into a true trend reversal may depend on whether buyers can push the price beyond the $1.40 trigger level.

Nigel Farage has taken a stake in a bitcoin treasury company led by former UK chancellor Kwasi Kwarteng, deepening links between the crypto sector and the populist political movement led by Nigel Farage.

Farage invested £215,000 in Stack BTC through his media company Thorn In The Side Ltd, according to disclosures tied to a fundraising round for the London-listed firm. The purchase gives the leader of Reform UK a stake of about 6.3% in the company.

The investment forms part of a £260,000 capital raise that also included participation from Blockchain.com. Stack issued 5.2 million new shares at 5 pence each, with the shares set to trade on the Aquis Growth Market.

Farage’s Bitcoin advocacy Nigel Farage’s investment aligns with his long-term vision to integrate Bitcoin into the U.K.’s financial landscape.

“I have long been one of the UK’s few political advocates for bitcoin,” Farage said. “London and the UK have served as a center of global finance, and the country should aim to serve as a global hub for the crypto industry.”

In May 2025, during the Bitcoin 2025 conference in Las Vegas, he pledged to create a Bitcoin reserve at the Bank of England and introduce legislation that would favor the adoption of Bitcoin if he were to become Prime Minister.

Farage’s pledge includes fostering a regulatory environment that encourages Bitcoin integration into traditional financial systems.

Reform UK also became the first European party to accept Bitcoin donations. Partnering with UK-based payment firm Radom, the party aims to modernize fundraising and engage supporters interested in Bitcoin, reinforcing Farage’s role in crypto politics.

Nigel Farage has argued that the state could hold bitcoin as part of a sovereign wealth structure tied to technology and financial infrastructure.

The party also counts major crypto investor Christopher Harborne among its financial backers. Harborne, a businessman with ties to digital asset trading and venture investment, has contributed large sums to the party over the past several years.

Stack BTC’s role in Bitcoin treasury management Stack BTC plays a pivotal role in helping corporations and institutions manage their Bitcoin holdings effectively.

The firm specializes in secure storage solutions, risk management strategies, and advisory services to help businesses integrate Bitcoin into their treasury operations.

By acquiring a stake in Stack BTC, Farage aims to enhance the firm’s capabilities, facilitating the adoption of Bitcoin among UK businesses as a viable treasury asset.

Micah Zimmerman

Micah first discovered Bitcoin in 2018 but remained a skeptic on the sidelines for too long. Since 2021, he has covered crypto and business and now works as a news reporter for Bitcoin Magazine, based in North Carolina.

Morning Minute is a daily newsletter written by Tyler Warner. The analysis and opinions expressed are his own and do not necessarily reflect those of Decrypt. Subscribe to the Morning Minute on Substack.

GM!

Today’s top news:

Crypto majors rebound overnight as oil drops from $115 to $100; BTC at $69K Polymarket and Kalshi reportedly raise at $20B valuations Florida aims to sign new stablecoin bill into law Circle and Stripe are both investing heavily in stablecoin infrastructure for AI Kast raises $80M to expand its stablecoin-powered neobank across borders 🛢 Bitcoin Swings as Iran Conflict Sends Oil HigherCrypto markets saw renewed volatility over the weekend as geopolitical tensions escalated in the Middle East.

Oil prices surged as the conflict involving Iran threatened supply routes around the Strait of Hormuz, a corridor responsible for roughly 20% of global oil shipments. Oil briefly surged past $115/barrel in Sunday night trading, driving stocks and crypto lower.

Bitcoin went as low as $65.6K before rebounding to $69K this morning as oil has fallen closer to the $100/barrel level.

Even with the rebound, Bitcoin is now trading back in its $60K-$70K range after a failed breakout run last week where Bitcoin ripped to $74K before falling.

And now it appears the price of “digital gold” is at least somewhat dependent on oil…

Key Details

• Oil briefly pushed above $115 as markets priced in potential Hormuz disruption
• Roughly 20% of global oil supply passes through the Strait of Hormuz
• Crypto markets sold off Sunday night but rebounded into Monday morning

📊 Prediction Markets Are Chasing $20B ValuationsPrediction market platforms Polymarket and Kalshi are reportedly raising new capital at valuations approaching $20 billion, according to the Wall Street Journal.

The platforms allow users to trade on the probability of real-world events ranging from elections and geopolitics to economic data and financial markets.

Interest in the sector exploded during the 2024 election cycle, when prediction markets saw billions in trading activity and became widely cited indicators of political sentiment.

Investors now appear eager to fund the next stage of growth.

Key Details

• Kalshi reportedly generated $466M in daily trading volume during recent peaks
• Prediction markets saw $4B+ weekly volume during the U.S. election cycle
• Kalshi raised $1B in Dec 2025 at an $11B valuation, and Polymarket’s last raise was $2B at $9B valuation led by ICE

🏛 Florida Close to Stablecoin Bill PassageThe Florida Senate has passed a new bill creating a legal framework for stablecoin payments, becoming one of the first U.S. states to pass comprehensive legislation focused specifically on stablecoins.

The law outlines rules around reserve backing, disclosures, and consumer protections for issuers operating in the state. Florida Governor Ron DeSantis will review the bill soon, a representative told Decrypt, and is expected to sign it into law.

While Congress continues debating federal crypto legislation, several states are beginning to move forward with their own frameworks.

Key Details

• Bill establishes reserve backing and transparency requirements for issuers
• Law allows stablecoins to be used for payments and financial settlement within the state
• It comes as Congress continues debating federal market structure legislation including the CLARITY Act

🤖 Stripe and Circle Are Building AI Payment RailsTwo of the biggest fintech companies in the world are racing to build payment systems designed for a future where autonomous AI agents transact using stablecoins.

Circle and Stripe are both investing heavily in infrastructure that allows machines to send payments automatically for things like compute, APIs, and data services.

Traditional payment networks were built for human transactions.

Stablecoins, however, offer instant global settlement and programmable payments, making them well-suited for machine-to-machine commerce.

Key Details

• Circle’s USDC processed $11.9T in transaction volume in 2025
• Stripe processed $1.9T in payment volume last year
• Machine-to-machine payments are expected to become a core component of the AI economy

🕵️ $46M Crypto Theft From U.S. Government WalletsU.S. authorities have arrested John Daghita, the son of a federal contractor, and charged him with stealing $46M in crypto from wallets controlled by the U.S. Marshals Service, which manages digital assets seized in criminal investigations.

According to prosecutors, the funds were part of the U.S. government’s growing strategic crypto stockpile, which includes Bitcoin and other digital assets confiscated in federal cases.

The suspicious transactions were first identified by on-chain investigator ZachXBT, whose analysis flagged unusual movements from government-controlled wallets.

Authorities allege Daghita gained access to sensitive wallet information through his father, who worked as a contractor involved in supporting the Marshals Service’s crypto custody operations.

Investigators say the stolen funds were then rapidly moved across multiple wallets and exchanges in an attempt to obscure the trail.

Key Details

• Suspect identified as John Daghita, the son of a federal contractor
• Funds stolen from U.S. Marshals–controlled wallets holding seized crypto
• Theft first uncovered through on-chain analysis by ZachXBT
• Prosecutors say the suspect attempted to launder the funds across multiple wallets

🌎 Macro Crypto and Markets Crypto majors are rebounding as oil cools off; BTC up 2.3% at $69K; ETH +3.6% at $2,017; SOL +3.8% at $85 DEXE (+18%), TAO (+8%) and CHZ (+5%) led top movers Oil is trading at $101 on Hyperliquid after hitting $115+ overnight Corporate Treasuries & ETFs The Bitcoin ETFs saw $349M in net outflows on Friday, ending the week with $569M in net inflows Strategy's STRC moved another 1.87M shares on Friday, giving Saylor capital to buy another 1,069 BTC (a new record) Meme Coin Tracker

Meme majors are rising; DOGE +3%, SHIB +2.6%, PEPE +2.9%, TRUMP -2.3%, PENGU +6.4%, SPX +0.7%, FARTCOIN -0.2% OIL (+50%), SOS (+100%) and Buttcoin (+13%) led on-chain movers 💰 Token, Airdrop & Protocol Tracker KAST raised an $80M Series A to build a stablecoin-powered cross-border payments platform Tether invested in Utexo, a startup aimed at bringing USDT and stablecoins to Bitcoin 🚚 What is happening in NFTs? NFT leaders were mostly flat; Punks even at 29.9 ETH, Pudgy +1% at 4.4 ETH, BAYC -2% at 5.7 ETH; Hypurr’s -2% at 440 HYPE XCOPY - Known Origin (+12%) led notable movers Pudgy Penguins teased a Pudgy World announcement coming today An exploit on Gondi has led to some NFTs being stolen and people are encouraged not to use the platform until resolved Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Expanded institutional participation underscores growing demand for private market opportunities and standardized operating infrastructure

, /PRNewswire/ -- Corastone, the hyperscaler for private-market investing, today announced Fidelity Investments, Future Standard, and Hamilton Lane (Nasdaq: HLNE) as investors in Corastone and its alternative-investing operating platform.

This growing institutional participation builds on Corastone's recent platform launch and comes as demand for private markets investments expands across investor types. As global private markets investment activity and volumes rise, firms are increasingly seeking transaction technologies that can perform at scale while meaningfully lowering operational friction and manual interventions. Corastone, through its proprietary private, permissioned blockchain network, is increasingly functioning as the shared network infrastructure and data standard for private markets workflows — replacing legacy file-based processes and point-to-point integrations with a single solution that supports straight-through processing for all market participants.

"As access to private markets continues to scale, firms need standardized, digital infrastructure that supports higher volumes and more complex structures without adding operational burden," said Hamid Gayibov, Co-Founder and President of Corastone. "Corastone was built to serve as a common operating layer for the ecosystem, and adding Fidelity, Future Standard and Hamilton Lane reflects how the industry is coalescing around shared, enterprise-ready infrastructure. Our goal is to help investors of all sizes access private market assets as efficiently and reliably as public markets."

Unlike legacy approaches that rely on multiple disconnected systems and point-to-point integrations, Corastone connects general partners, wealth managers, and administrators on a single, shared private markets platform. This unified architecture helps firms scale activity across asset types and volumes without increasing operational complexity.

Client Quotes

Future Standard - "As private markets continue to expand across wealth and institutional channels, we saw a need in the marketplace for an infrastructure technology that connects the various point-to-point systems used by investors and enables true straight-through-processing of transactions. We adopted Corastone because it provides a modern, scalable approach to delivering this connective layer for the industry, and does so in a way that improves transparency, controls, and investor experiences. Our decision to invest reflects our confidence in the platform's long-term role in facilitating the growing demand for private markets investments." – Hari Moorthy, Chief Technology Officer at Future Standard Hamilton Lane - "We've seen firsthand how operational complexity can limit participation in private markets, and have prioritized building or investing in technology that aims to enhance transparency and efficiency. Corastone's platform removes that friction, which we believe will help unlock the industry's next growth phase." – Griff Norville, Head of Technology Solutions at Hamilton Lane With Fidelity Investments, Future Standard and Hamilton Lane investing in the platform, Corastone's institutional footprint continues to expand. This follows recent momentum across the ecosystem, with participants such as Apollo, Franklin Templeton, KKR, and Morgan Stanley using Corastone's technology to modernize private market distribution.

About Corastone

Corastone is the hyperscaler for private market investing, providing the modern infrastructure that enables straight-through processing for GPs, wealth managers and fund administrators. Through a single integration, participants gain access to a vast ecosystem of investment opportunities and counterparties, helping them grow their business with confidence. Solely focused on infrastructure, Corastone enables consistent, repeatable processes throughout the investment lifecycle, fostering visibility, control and seamless operations. Built on a permissioned blockchain, Corastone is purpose-built to support new workflows, innovative products and the rapidly evolving private markets. For more information, visit corastone.us.

Fidelity Investments® is an independent company, unaffiliated with Corastone. Fidelity Investments is an investor in Corastone and is not affiliated with any other company noted herein and doesn't endorse or promote any of their products or services. Fidelity Investments is a registered trademark of FMR LLC. Fidelity Investments® provides investment products through Fidelity Distributors Company LLC; clearing, custody, or other brokerage services through National Financial Services LLC or Fidelity Brokerage Services LLC, Members NYSE, SIPC.

eReview # 1252854.1.0

About Future Standard

Future Standard is a global alternative asset manager serving institutional and private wealth clients, investing across private equity, credit and real estate. With a 30+ year track record of value creation and $86 billion in assets under management, we back the business owners and financial sponsors that drive growth and innovation across the middle market, transforming untapped potential into durable value.1

1 Total AUM estimated as of September 30, 2025.

About Hamilton Lane

Hamilton Lane (Nasdaq: HLNE) is one of the largest private markets investment firms globally, providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 780 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has $1.0 trillion in assets under management and supervision, composed of $146.1 billion in discretionary assets and $871.5 billion in non-discretionary assets, as of December 31, 2025. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit our website or follow us on LinkedIn.

Media Contact

Forefront Communications for Corastone
[email protected]

SOURCE Corastone

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

Copyright 2026 Zacks Investment Research 101 N Wacker Drive, Floor 15, Chicago, IL 60606

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.

Visit Performance Disclosure for information about the performance numbers displayed above.

Visit www.zacksdata.com to get our data and content for your mobile app or website.

Real time prices by BATS. Delayed quotes by Sungard.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.

This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.

By Reuters

March 9, 20261:06 PM UTCUpdated 6 mins ago

Live Nation Entertainment logo is seen in this illustration taken May 23, 2024. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

CompaniesMarch 9 (Reuters) - Live ​Nation Entertainment (LYV.N), opens new tab ‌has ​reached ​a proposed ⁠settlement ​with ​the U.S. Justice ​Department, ​according to ‌a ⁠court hearing ​on ​Monday.

Make sense of the latest ESG trends affecting companies and governments with the Reuters Sustainable Switch newsletter. Sign up here.

Reporting ⁠by ​Kritika ​Lamba ⁠in Bengaluru; ⁠Editing ​by ​Krishna ​Chandra Eluri

Our Standards: The Thomson Reuters Trust Principles., opens new tab

New platform connects devices, data and care teams across the patient journey to streamline operations and enhance outcomes for patients and staff

, /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced its new SmartHospital Platform, a digital foundation designed to connect devices, data and care teams across the hospital into one intelligent, adaptive ecosystem. The launch comes ahead of the 2026 HIMSS Global Conference & Exhibition and marks a significant expansion of Stryker's digital offerings.

Stryker launches the SmartHospital platform. The SmartHospital Platform is being led by Stryker's new Smart Care business, established to advance the company's ongoing commitment to supporting their customers' digital transformations. Built to help address today's healthcare challenges, including system fragmentation, staff overload and high patient volumes, the SmartHospital Platform scales to support the unique needs of hospitals and health systems, surfacing relevant insights to inform clinical decisions and enhance workflow efficiency.

"We are dedicated to partnering with our customers on their digital journeys to help elevate care delivery," said Scott Sagehorn, VP/GM of Smart Care at Stryker. "The SmartHospital Platform is designed to evolve alongside health systems so teams can work more efficiently and stay focused on patient-centered care."

Key capabilities of the SmartHospital Platform include:

Connected infrastructure: The platform connects devices and data to support clinical and operational workflows across transport, treatment and recovery, helping teams better coordinate patient care. Clinical communication: Voice-activated, hands-free communication devices such as Stryker's Sync Badge give teams critical information and prioritized alarms to support timely, coordinated care delivery across the hospital. Workflow engine: Engage, the intelligent middleware engine behind the SmartHospital Platform, helps reduce communication silos by filtering and prioritizing alarms and notifications so staff can stay informed across busy care settings. Virtual care: Virtual nursing and virtual monitoring workflows help support bedside staff by streamlining administrative tasks and empowering them to stay focused on the patient experience. Ambient intelligence: Ambient sensors, computer vision, AI and contextual data help the care environment become more aware, adaptive and responsive. "Launching the SmartHospital Platform is an important step forward in supporting our customers as they transform care delivery," said Jessica Mathieson, president of Medical at Stryker. "We remain focused on solving problems, helping nurses and staff spend less time navigating complexity and more time with patients."

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

To learn more about the SmartHospital Platform, visit stryker.com/smarthospitalplatform 

Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
[email protected]  

SOURCE Stryker

Kevin Book, ClearView Energy Partners managing director, joins 'Squawk Box' to discuss the spike in oil prices, how far higher prices can go, impact of high oil prices on China and Russia, state of the U.S. Strategic Petroleum Reserve, and more.

CHONGQING, CHINA - JANUARY 22: In this photo illustration, a smartphone displays the logo of Corning Incorporated (NYSE: GLW), an American materials science company known for specialty glass, ceramics and optical fiber products used in consumer electronics, telecommunications, automotive and industrial applications, in front of a screen showing the company's latest stock market chart on January 22, 2026, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Getty Images

Corning, a leader in materials science focusing on specialty glass and fiber optics, experienced a sharp sell-off after the CEO of significant competitor Broadcom moderated expectations for short-term demand in optical fiber for AI data centers. This development directly contradicted GLW‘s main growth narrative, which had driven the stock to new heights, resulting in a high-volume, aggressive decline.

Following such a substantial surge, is this a fundamental change in the AI infrastructure story or merely a sentiment correction of an overvalued stock?

The Fundamental ReasonThe downturn indicates a revaluation rather than a true collapse in demand. Broadcom’s remarks injected near-term uncertainty into a crowded marketplace, compelling investors to reevaluate the timing and scale of AI-related revenue across the optical components sector.

Broadcom CEO Hock Tan publicly downplayed the immediate demand for optical fiber in AI data centers.The sell-off was intensified by the stock’s considerable previous rally and high valuation metrics.Increased insider selling and reductions in institutional holdings in early 2026 indicated a rising level of caution.However, what’s intriguing is that you are reading about this -8.5% move after it has occurred. The market has already factored in the news. To preempt the next underperformer before it hits the headlines, you require predictive signals, not just notifications. High Quality Portfolio has a risk model designed to minimize exposure to underperforming assets.

The Holistic Price Action PictureThe price structure unveils a complex narrative beneath today's headline movement.

MORE FOR YOU

The current trend is designated as Trending Up: Prices are above the rising 50D and 200D moving averages. The institutional trend seems to remain intact.

Currently priced at $123.29, the stock is 235.4% above its 52-week low of $36.76 and 23.8% below its 52-week high of $161.8.

Trend Regime: Trending Up The 50D SMA slope is at 22.8%, indicating that the primary trend is rising.Momentum Pulse: Decelerating: Positive but short-term annualized return is underperforming relative to longer-term performance. Momentum is waning but the trend is intact. This could lead to consolidation. The 5D return is -18.0% while the 20D return is 9.5%, compared to 63D returns of 47.8% and 126D returns of 77.8%.Key Levels to Watch: The nearest resistance is at $161.8 (31.2% away, 1 prior touch). The nearest support level is at $122.38 (0.7% below current price, one prior touch). The current risk/reward ratio stands at 42.32x – indicating greater upside to resistance compared to downside to support from this point.Volatility Context: Expanded: The 20D realized volatility is 80.0% annualized compared to the 1-year average of 43.8% (compression ratio: 1.82x). The expected daily move is approximately 7.86% of price – suggesting that large fluctuations continue to be common and trend signals should be interpreted with caution until volatility diminishes.Grasping price structure, money flow, and price behavior can provide you with a competitive advantage. See more.

What Next?The immediate technical challenge for GLW lies in the $122.38 zone, a previous support level. Continued selling at or beneath this zone could heighten the risk of further declines, but a singular day's price action does not affirm a long-term trend.

To assess whether this volatility is structurally warranted, it is essential to consider the broader picture. You should compare this recent price move to the company's growth, multiples, margins, and core investment thesis at the GLW Investment Highlights.

A -8.5% single-day move serves as a stark reminder of the inherent volatility in choosing individual stocks. While everyone aspires to capture a significant increase, experiencing a sudden drop like this is an unavoidable aspect of concentrated investments. For investors prioritizing steady growth over predicting specific catalysts, a balanced investment strategy naturally mitigates this type of single-stock volatility. If you favor a more systematic approach to risk management, portfolios act as a structured method to navigate through these market cycles.

Portfolios Are The Smarter Way To InvestIndividual stocks are unpredictable. An intelligent portfolio aids in investing, limits downside shocks, and offers upside potential.

Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse selection of 30 stocks that have collectively provided stronger returns with reduced volatility compared to the broader market indices. Uncover the methodology behind these more stable, higher returns by reviewing the HQ Portfolio performance data.

3D Systems (DDD - Free Report) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -30.00%. A quarter ago, it was expected that this maker of 3D printers would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of +11.11%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

3D Systems, which belongs to the Zacks Commercial Printing industry, posted revenues of $106.28 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 7.87%. This compares to year-ago revenues of $111.02 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

3D Systems shares have added about 10.7% since the beginning of the year versus the S&P 500's decline of 1.5%.

What's Next for 3D Systems?While 3D Systems has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for 3D Systems was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $90.92 million in revenues for the coming quarter and -$0.39 on $374.73 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Commercial Printing is currently in the top 21% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

UniFirst (UNF - Free Report) , another stock in the broader Zacks Industrial Products sector, has yet to report results for the quarter ended February 2026.

This uniform provider is expected to post quarterly earnings of $1.21 per share in its upcoming report, which represents a year-over-year change of -13.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

UniFirst's revenues are expected to be $613 million, up 1.8% from the year-ago quarter.

DENVER, COLORADO / ACCESS Newswire / March 9, 2026 / Crestone Air Partners, a global aviation asset management platform majority owned by Air T, Inc. (NASDAQ:AIRT), has entered into a definitive agreement to acquire Arena Aviation Capital, a well-established aviation asset manager with a diversified portfolio and deep airline relationships. The transaction is subject to closing conditions and approvals.

The acquisition materially expands Crestone's aviation lifecycle platform, enhancing its size and breadth of capabilities. Upon closing, the combined platform is expected to comprise approximately 124 aircraft and 17 engines on lease to customers globally, with over US$4 billion of assets under management and more than 55 employees across 5 countries, strengthening Crestone's position as a leading full-service aviation asset manager headquartered in Denver with a broad operating footprint.

Arena brings a seasoned team, a complementary portfolio, and deep expertise that aligns closely with Crestone's lifecycle-oriented investment approach. The combined organization will maintain offices in Denver, Amsterdam, and Dublin, with satellite presences in Singapore and Buenos Aires, supporting airline relationships globally.

"This transaction is a natural strategic fit and reflects our belief that the industry benefits from disciplined consolidation," said Kevin Milligan, CEO and Co-Founder of Crestone Air Partners. "Global coverage and scaled capital are essential to delivering durable value. Arena brings a highly respected team, with an excellent track record, strong technical capabilities, and long-standing relationships with aircraft owners and airlines."

"For Arena, this transaction marks an important milestone following more than a decade of building the business," said Patrick den Elzen, CEO of Arena Aviation Capital. "I am immensely proud of what my partners and our team have achieved, growing Arena into a trusted and respected aircraft lease management platform. We believe joining Crestone is the right next chapter, creating new opportunities for our team, strengthening our offering to investor clients, and positioning the platform for long-term success."

A portion of Arena Aviation Capital's management team will play key roles within the combined organization. Crestone anticipates a seamless integration focused on continuity for airline customers, capital partners, and employees. The combined group will leverage synergies across asset management, technical services, lease administration, and market intelligence, enabling more efficient operations and enhanced support for aircraft owners throughout the asset lifecycle.

Crestone was advised by Pillsbury Winthrop Shaw Pittman LLP as legal counsel, Kroll, LLC as financial advisor, and PwC on tax matters.

About Crestone Air Partners

Crestone Air Partners, Inc. (CAP) invests in commercial jet aircraft and the engines that power them on behalf of our capital partners. We are a full-service aviation asset management platform with a diverse portfolio of aircraft and engines leased to airlines globally. We target transactions throughout the asset lifecycle, taking a collaborative approach with our clients by offering flexible lease terms tailored to our customers' requirements. Crestone brings unique value to transactions by drawing on the expertise and capabilities of interrelated aviation specialist subsidiary businesses across the Air T family (airframe material sales, landing gear leasing, engine material sales, disassembly, and aircraft storage). Crestone is headquartered in Denver, Colorado, and is a business unit of Air T, Inc. holding company (NASDAQ:AIRT). Additional information can be found at: www.crestoneairpartners.com.

About Arena Aviation Capital

Arena Aviation Capital (www.arena-aviationcapital.com) is a full-service aircraft investment management company focusing on the complete life cycle of acquiring and leasing used commercial aviation assets, servicing investment and airline customers worldwide, and providing services including the origination, financing, risk management, and administration (finance/accounting and legal) of commercial aviation assets. Arena today manages aircraft and engines leased to airline customers worldwide.

About Air T, Inc.

Established in 1980, Air T Inc. is a portfolio of powerful businesses and financial assets, each of which is independent yet interrelated. Its core segments are overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. We seek to expand, strengthen and diversify Air T's after-tax cash flow per share. Our goal is to build Air T's core businesses, and when appropriate, to expand into adjacent and other industries. We seek to activate growth and overcome challenges while delivering meaningful value for all stakeholders. For more information, visit www.airt.com.

Contact

Richard Schact
SVP, Finance & Operations
[email protected]

SOURCE: Air T, Inc.

Fonseca brings decades of leadership in digital transformation, strategic growth, and scaling complex marketplaces to the Rent the Runway Board of Directors Fonseca brings decades of leadership in digital transformation, strategic growth, and scaling complex marketplaces to the Rent the Runway Board of Directors

, /PRNewswire/ -- TriNet (NYSE: TNET), a leading provider of comprehensive human resources solutions for small and medium-size businesses (SMBs), today announced the results of a new survey conducted with Harvard Business Review Analytic Services. Among 230 survey respondents familiar with their SMB's U.S. talent practices, 'The New Talent Playbook for Small and Midsize Businesses in the Age of AI' reveals that 76% expect their organization to increase its use of AI in the next 12 months, highlighting the technology's growing presence in everyday operations. However, just 19% of respondents feel their organization is highly prepared to recruit or develop the AI skills needed, underscoring a widening capability gap."

Harvard Business Review Analytic Services Survey, Sponsored by TriNet, Finds SMBs Accelerating AI Adoption and Embracing New Opportunities for Workforce Skill Development "AI is fundamentally transforming the way SMBs operate," said Catherine Wragg, Chief People Officer at TriNet. "At TriNet, our commitment to putting SMB customers at the center of everything we do drives us to understand their evolving needs. This research underscores that while SMBs are moving swiftly to embrace AI, many are still navigating the best ways to equip their people for this new era." She continued, "Embracing AI presents an opportunity to not only adopt new technology, but also to reimagine workforce strategies, planning, and skill development, empowering SMBs to accelerate AI adoption and unlock exciting new avenues for workforce growth and success."

Key Survey Findings

56% of those surveyed expect AI will require their SMB to develop or train employees differently. 49% anticipate changes in existing roles and responsibilities due to AI. 56% expect difficulty determining which AI skills their organization actually needs. Looking ahead, 55% say one of the most in demand AI-related skills will be experience using AI tools to accomplish work tasks. 70% report AI is driving the need to find talent with human capabilities such as creativity, intuition, and discernment to work with AI. SMBs are already feeling pressure to expand internal AI capabilities. Nearly half of respondents (49%) anticipate difficulty training/upskilling existing employees on AI, while 37% expect challenges evaluating candidates' AI skills and experience. Despite these challenges, SMBs remain committed to future ready talent development: 79% of respondents agree that AI is driving the need to upskill existing talent.

The report also highlights emerging emphasis on human-centered skills that AI cannot replicate, resulting in a growing focus on human-AI collaboration. Many SMBs prioritize industry experience, emotional intelligence, and judgment foundational qualities required to ensure AI is deployed ethically and effectively.

Download the full Harvard Business Review Analytic Services survey here.

About TriNet
TriNet is a leading provider of Human Resources solutions for small and medium-size businesses, offering advanced technology-enabled services that include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. Our long-term objective is to be the premier provider of HR services for a broad range of SMBs through industry leading benefits, sales distribution excellence, and a world class services delivery model. For more information, visit TriNet.com or follow us on Facebook, LinkedIn and Instagram.

SOURCE TriNet

Editas Medicine (EDIT - Free Report) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +77.78%. A quarter ago, it was expected that this genome editing company would post a loss of $0.38 per share when it actually produced a loss of $0.28, delivering a surprise of +26.32%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Editas, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.74 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 280.05%. This compares to year-ago revenues of $30.6 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Editas shares have lost about 2.4% since the beginning of the year versus the S&P 500's decline of 1.5%.

What's Next for Editas?While Editas has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Editas was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $2.4 million in revenues for the coming quarter and -$1.13 on $22.04 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

MeiraGTx Holdings PLC (MGTX - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025.

This company is expected to post quarterly loss of $0.60 per share in its upcoming report, which represents a year-over-year change of -20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

MeiraGTx Holdings PLC's revenues are expected to be $2.41 million, down 88.7% from the year-ago quarter.

An updated edition of the January 15, 2026 article.

Nuclear energy is increasingly being recognized as a critical solution to meet the world’s rising demand for clean electricity. As utilities continue transitioning toward low-carbon power sources, nuclear plants stand out for their ability to deliver dependable, carbon-free generation. Unlike solar and wind power, which are weather-dependent, nuclear energy provides consistent, around-the-clock output.

The renewed momentum in the sector is reflected in the extension of operating licenses for existing reactors, ongoing development of Small Modular Reactors (SMRs), approvals for the construction of new nuclear facilities, and the restart of previously shut U.S. reactors. Investments from major technology companies to support SMR development further underscore the growing investor interest in nuclear energy stocks.

In the United States, new policies aim to expand nuclear capacity from roughly 100 gigawatts (“GW”) in 2024 to about 400 GW by 2050. The nuclear energy sector is gaining momentum as it supports global decarbonization goals.

Favorable regulations and ongoing R&D in advanced SMRs are strengthening its outlook. Meanwhile, rising demand for reliable 24/7 clean power from AI data centers, manufacturing reshoring and electric vehicles is creating new growth opportunities. Government initiatives to boost domestic uranium supply are further supporting the sector’s momentum.

With this increasing importance, nuclear energy-related stocks, such as Entergy Corporation (ETR - Free Report) , Nano Nuclear Energy Inc. (NNE - Free Report) and NexGen Energy (NXE - Free Report) , are becoming attractive investment options. Unlike other clean energy sources affected by intermittency, nuclear power plants provide a consistent and stable energy output, operating around the clock except during planned maintenance intervals.

Compared with other clean energy sources, nuclear power requires significantly less land to generate the same amount of clean electricity. Additionally, while all traditional energy sources produce waste, nuclear energy stands apart for its highly regulated, secure and systematic approach to waste management and storage. Increasing adoption of electric vehicles, rising demand from the power grids and the development of large artificial intelligence-powered data centers are increasing the importance of nuclear power plants.

Nuclear Energy stocks have huge potential and can offer significant growth opportunities for investors. Our Nuclear Energy Screen makes it easier for investors to locate high-potential stocks at any given time. Apart from the stocks mentioned above, investors can also explore stocks like Denison Mines Corp. (DNN - Free Report) and BHP Group Limited (BHP - Free Report) , as these companies ensure the supply of uranium for the smooth running of nuclear power plants.

Ready to uncover more transformative thematic investment ideas? Explore 36 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.

Entergy Corporation’s nuclear energy portfolio supports its long-term growth strategy and transition to cleaner energy. As of Dec. 31. 2025, the company’s major nuclear plants generated around 21% of its total power capacity. Entergy is actively pursuing license extensions and system upgrades at these facilities, targeting an additional 275 MW through uprates. These enhancements not only increase generation but also highlight Entergy’s ongoing commitment to delivering stable, carbon-free baseload electricity. The company has taken initiatives to add 40 MW at its River Bend nuclear plant in Louisiana.

Entergy is advancing efforts to explore next-generation nuclear technologies to further lower emissions. The company has secured a permit in Mississippi for a potential new reactor site and is working to engage industrial customers and technology firms, particularly those in the AI and data sectors. These partnerships aim to collaboratively address the financial and regulatory challenges associated with developing next-generation nuclear projects.

Entergy’s nuclear expansion is gaining momentum as electricity demand rises from AI-driven industries and large data centers. Supported by strong market demand and a forward-looking strategy, the company’s nuclear initiatives are well-positioned to enhance regional energy reliability and advance broader U.S. decarbonization goals.

This Zacks Rank #2 (Buy) company intends to invest $43 billion during the 2026-2029 period to fund the company's generation fleet transition and grid modernization, and expand its zero-carbon generation portfolio.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Nano Nuclear Energy Inc. is a microreactor developer, aiming to become the leading advanced nuclear microreactor developer in North America. The company is advancing KRONOS toward licensing and already has a pipeline of potential commercial customers and strategic partners in the United States and globally for its KRONOS MMRTM system.

Uranium plays a vital role in the successful operation of nuclear power plants. The company continues to address the key bottlenecks within the nuclear fuel supply chain and is in discussion with different providers for securing a dependable uranium source for NANO Nuclear Energy’s future fuel requirements.

Nano Nuclear Energy has completed the assembly of its proprietary Annular Linear Induction Pump technology prototype and expects to begin commercial sales efforts. The milestone demonstrates the company’s ability to advance its technology from initial design through construction and successful demonstration.

This Zacks Rank #2 company has a growing pipeline of opportunities with potential AI data center, industrial and military-related customers for its KRONOS MM system.

NexGen Energy is emerging as an important player in the global nuclear fuel supply chain, led by its flagship Rook I uranium project in Canada’s Athabasca Basin. As nuclear power gains renewed importance in the global energy transition, the company is well-positioned to benefit from rising uranium demand. Government support for nuclear generation to meet decarbonization goals and rising electricity consumption creates a favorable environment for uranium developers like NexGen Energy.

NexGen Energy reached a key milestone in 2026 after securing final approval from the Canadian Nuclear Safety Commission to begin site preparation and construction of the Rook I project. Once operational around 2030, the project could produce up to 30 million pounds of uranium annually and will be ready to meet the demand from nuclear power plants.

Zacks #2 Ranked NexGen Energy’s long-term outlook remains favorable as global interest in nuclear power rises and uranium supply tightens. Increasing electricity demand from AI technologies and large data centers is expected to boost nuclear expansion and uranium consumption. Backed by a high-quality resource base and a clear path to production, the company is well-positioned to become a leading uranium supplier and generate long-term investor value.

BROSSARD, Quebec, March 09, 2026 (GLOBE NEWSWIRE) -- Please note that the version of the release issued earlier today by G Mining Ventures Corp. (TSX:GMIN, OTCQX:GMINF) was incorrect. The correct version of the release follows: 

G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX:GMIN, OTCQX:GMINF) announces that the Corporation’s largest shareholder, La Mancha Investments S.à r.l. (“La Mancha”), has elected to exercise its top-up right pursuant to the investor rights agreement between the Corporation and La Mancha that was initially entered into on July 22, 2022 and subsequently updated on July 15, 2024, which allows La Mancha to increase its ownership to up to 19.9%. This transaction represented the final opportunity for La Mancha to exercise its right to increase its ownership to such level, after which La Mancha retains only customary anti-dilution rights.

Louis-Pierre Gignac, President and Chief Executive Officer, stated: “This additional investment by La Mancha further demonstrates its long-term support and its strong conviction in our ability to create shareholder value as we continue our evolution into a leading intermediate gold producer.”

In connection with the exercise of La Mancha’s long-standing top-up right, the Corporation has agreed to issue 9,311,745 common shares (the “Top-Up Shares”) to La Mancha at a price of CAD45.89 per Top-Up Share, for aggregate gross proceeds of approximately CAD427 million. There are no fees or commissions payable on the La Mancha subscription, which is expected to close on or about March 11, 2026, subject to customary closing conditions, including receipt of the Toronto Stock Exchange approval. Following the issuance of the Top-Up Shares, La Mancha will beneficially own approximately 19.9% of the issued and outstanding common shares of the Corporation.

Vincent Benoit, Managing Partner and Chief Investment Officer of La Mancha, commented: “The investment reflects that La Mancha continues to see significant value creation potential in the Corporation. G Mining’s strong performance and execution to date have reinforced La Mancha’s original investment thesis, which remains firmly supported by the Corporation’s growth strategy, portfolio of high-quality gold assets in Latin America, and highly experienced management team with a proven track record of building and operating mines.”

The Oko West Gold Project remains on-budget and on-schedule for first gold pour in the second half of 2027 and continues to be fully funded by the Corporation’s balance sheet and cash flow. The Corporation intends to use the proceeds from the issuance of the Top-Up Shares to reduce reliance on debt pertaining to Oko West Project development, increase exploration efforts, accelerate debt repayment, and for general corporate purposes.

Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions

La Mancha is a related party to the Corporation and as such, the issuance of the Top-Up Shares to La Mancha constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Corporation is relying on exemptions from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a) in respect of such issuance as the fair market value of the transaction does not exceed 25% of the Corporation's market capitalization.

About G Mining Ventures Corp.
G Mining Ventures Corp. is a mining company engaged in the development, operation and exploration of precious metal projects to capitalize on the value uplift from successful mine development. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored in mining-friendly jurisdictions: Brazil, with the Tocantinzinho Gold Mine and the Gurupi Project as well as Guyana, with the Oko West Project. GMIN trades on the TSX under the symbol “GMIN”.

Additional Information 
For further information on GMIN, please visit the website at www.gmin.gold or contact:  

Jean-François Lemonde 
Vice President, Investor Relations 
514.299.4926
[email protected]

Cautionary Statement on Forward-Looking Information
All statements, other than statements of historical fact, contained in this press release constitute “forward-looking information” and “forward-looking statements” within the meaning of certain securities laws and are based on expectations and projections as of the date of this press release. Beforehand, it must be noted that this press release’s subject matter is forward-looking in its essence and nature. Forward-looking statements contained in this press release include, without limitation, those related to (i) the acceptance of the Subscription by the Toronto Stock Exchange; (ii) the satisfaction of the closing conditions relating to the Subscription; (iii) the timing relating to the closing of the Subscription; (iv) the use of proceeds relating to the Subscription; (v) the Corporation’s ability to create shareholder value and to continue its evolution into a leading intermediate gold producer; (vi) the budget and schedule of the Oko West Gold Project and, as usual, the section entitled “About G Mining Ventures Corp.”, as well as the quoted comments of GMIN’s President and Chief Executive Officer.

Forward-looking statements are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Such assumptions include, without limitation, those relating to the successful closing of the Subscription, the budget and schedule of the Oko West Gold Project and those underlying the items listed in the above section entitled “About G Mining Ventures Corp.”.

Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that, notably but without limitation, the Subscription will close successfully, as future events could differ materially from what is currently anticipated by the Corporation.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Corporation’s other filings with the securities regulators of Canada including, but not limited to, the cautionary statements made in the relevant sections of the Corporation’s (i) Annual Information Form dated March 27, 2025, for the financial year ended December 31, 2024, and (ii) Management Discussion & Analysis. The Corporation cautions that the foregoing list of factors that may affect future results is not exhaustive, and new, unforeseeable risks may arise from time to time. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway

RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.

Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA’s Center for Devices and Radiological Health (CDRH) seeking Premarket Approval (PMA).

Sangamo believes that the totality of data from the registrational STAAR study demonstrates the potential of isaralgagene civaparvovec as a one-time, well-tolerated and durable gene therapy treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift the Fabry treatment paradigm. Furthermore, the STAAR study demonstrated a positive mean annualized eGFR slope at 52-weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. These data were presented via four platform presentations and in poster presentations at the recent 22nd Annual WORLDSymposium™. These data are available on Sangamo’s website on the Presentations page.

About the STAAR Study
The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec, or ST-920, a gene therapy product candidate in patients with Fabry disease. Isaralgagene civaparvovec requires a one-time infusion without preconditioning. Isaralgagene civaparvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency.

About Fabry Disease
Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (α-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm; the potential for isaralgagene civaparvovec to qualify for and receive approval under the FDA’s accelerated approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civaparvovec; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo’s lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a commercialization partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that preliminary or topline data is not indicative of final results, that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; Sangamo’s need for substantial additional funding to execute its operating plan and to continue to operate as a going concern; the effects of macroeconomic factors or financial challenges on the global business environment, healthcare systems and Sangamo’s business and operations; the research and development process; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the potential for technological developments that obviate technologies used by Sangamo; Sangamo’s reliance on collaborators and the potential inability to secure additional collaborations; and Sangamo’s ability to achieve expected future financial performance.

All forward-looking statements about Sangamo’s future plans and expectations, including Sangamo’s development plans for its product candidates, are subject to Sangamo’s ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2024, as supplemented by its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

Contacts

Investor Relations and Media Inquiries
Louise Wilkie
[email protected]
[email protected]

, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:

Eurogin HPV Conference (Vienna, Austria)
Date: Thursday, March 19
Time: 8:00 AM CET
Presentation: DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRP

World Vaccine Congress DC (Washington, DC)
Date: Monday, March 30
Time: 11:50 AM ET
Presentation: Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, [email protected] 

SOURCE INOVIO Pharmaceuticals, Inc.

SAN JOSE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries, today announced it has entered into a multi-year license agreement with Advanced Micro Devices (AMD) for access to Adeia’s comprehensive semiconductor intellectual property (IP) portfolio. The agreement also resolves all outstanding litigation between the companies.

“We are pleased to reach this agreement with AMD, a global leader in high-performance computing and advanced semiconductor solutions,” said Paul E. Davis, chief executive officer of Adeia. “Resolving our disputes allows both companies to move forward and creates an opportunity for exploring future collaborations on advanced semiconductor technologies.”

Adeia has pioneered fundamental advances in the semiconductor industry over the last 30 years. With a large and growing portfolio of intellectual property covering hybrid bonding, semiconductor packaging and semiconductor processing technologies, Adeia licenses and partners with leading semiconductor companies around the world.

About Adeia Inc.

Adeia (Nasdaq: ADEA) is the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries. We invent and license foundational technologies that shape the future of digital entertainment, electronics, and high-performance computing. Our portfolio transforms technologies into an experience that is intelligent, immersive, and personal. For more, please visit www.adeia.com.

For Information Contact:

Adeia Investor Relations
Chris Chaney
[email protected]

Adeia Media Relations
Dr. Mark Kokes
[email protected]

Marketing Agreement Establishes Powerful National Distribution Channel and Expands Marpai's Revenue Growth Opportunity

, /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today announced the execution of a transformational marketing agreement dramatically expanding the national reach of its high-growth pharmacy benefit management division, providing access to a network representing up to 1.5 million covered employees for MarpaiRx.

The agreement creates a powerful new distribution channel for MarpaiRx's pharmacy benefit solutions and broader healthcare technology platform, enabling the Company to introduce its services to large employer groups, third-party administrators, and other healthcare organizations across the United States.

Through this collaboration, Marpai expects to gain access to a substantial pipeline of potential new business opportunities, significantly expanding the Company's addressable market and positioning MarpaiRx for accelerated growth.

Significant Revenue Opportunity

Management believes the scale of this distribution network represents a major strategic growth opportunity for the Company. Even modest adoption across this population of covered lives could represent a meaningful expansion of Marpai's pharmacy benefit management business.

The marketing agreement offers potential access of up to 1.5 million covered lives, representing a multiple of Marpai's current covered population and significantly expanding the Company's addressable market and long-term revenue opportunity. Within the pharmacy benefit management industry, revenue is typically generated on a per-member basis, meaning that as covered lives are added to the platform, they can contribute recurring revenue streams that scale with MarpaiRx's platform.

MarpaiRx's believes that its existing infrastructure is sufficiently robust to service the potential new members.

With the marketing agreement, Marpai expects opportunities to introduce its broader healthcare solutions across the same population, including third-party administration services, advanced healthcare analytics, and consulting capabilities.

"This agreement represents a major milestone for Marpai and a significant expansion of our potential growth runway," said Damien Lamendola, CEO of Marpai, Inc. "Gaining access to a network that could potentially reach up to 1.5 million employees dramatically expands our addressable market. Even modest penetration across this population of covered lives has the potential to create a substantial new revenue stream for MarpaiRx and accelerate the Company's overall growth trajectory."

Built for Scale

MarpaiRx provides a comprehensive suite of pharmacy benefit management services designed to reduce pharmacy costs for employers while improving member outcomes. The platform includes manufacturer rebate optimization, patient assistance programs, copay management solutions, and advanced healthcare analytics designed to help employers manage rising pharmacy costs.

The Company believes its transparent, technology-enabled PBM model positions MarpaiRx as an attractive alternative to traditional pharmacy benefit management offerings.

"Our MarpaiRx platform has been built specifically to scale across large populations of covered lives," said Mimi Davis, President of MarpaiRx. "This agreement gives us the opportunity to showcase our capabilities to a very large national audience while delivering meaningful pharmacy cost savings for employers and plan members."

Entering a New Phase of Growth

The marketing agreement significantly expands Marpai's distribution capabilities and positions the Company to pursue rapid growth within the large and expanding pharmacy benefit management market.

With scalable infrastructure already in place, Marpai believes the opportunity created by this partnership could support accelerating revenue growth and increasing operating leverage as additional covered lives are onboarded over time.

This agreement represents another important step in Marpai's strategy to rapidly expand the MarpaiRx platform and drive sustained revenue growth across the Company's healthcare technology ecosystem.

"We believe this agreement positions Marpai to enter a new phase of expansion, supported by a large and growing pipeline of potential covered lives," added Lamendola. "Our focus now is on executing against this opportunity and converting this significant market access into long-term recurring revenue and shareholder value."

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA, PBM and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $150 billion TPA sector serving self-funded employer health plans representing over $1.5 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://ir.marpaihealth.com.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses the potential access of up to 1.5 million covered lives which may significantly expand its addressable market, that the agreement dramatically expands the national reach of its high-growth pharmacy benefit management division, MarpaiRx, the potential benefits that may be derived as a result of the agreement, that MarpaiRx believes that its existing infrastructure is sufficiently robust to service the potential new members, that the agreement represents a major milestone and a significant expansion for the potential of its growth runway, that the agreement has the potential to create a substantial new revenue stream and accelerate its overall growth trajectory, its belief that its transparent, technology-enabled PBM model positions MarpaiRx as an attractive alternative to traditional pharmacy benefit management offerings and the potential for converting the significant market access into long-term recurring revenue and shareholder value. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

SOURCE Marpai

ARS Pharmaceuticals, Inc. (SPRY - Free Report) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -0.96%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.52, delivering a surprise of -15.56%.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

ARS Pharmaceuticals, Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $28.09 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 9.10%. This compares to year-ago revenues of $86.58 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

ARS Pharmaceuticals, Inc. shares have lost about 22.2% since the beginning of the year versus the S&P 500's decline of 1.5%.

What's Next for ARS Pharmaceuticals, Inc.?While ARS Pharmaceuticals, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for ARS Pharmaceuticals, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.44 on $25.86 million in revenues for the coming quarter and -$1.41 on $177.14 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Guardian Pharmacy Services (GRDN - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 11.

This provider of pharmacy services to long-term care facilities is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of +12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Guardian Pharmacy Services' revenues are expected to be $388.27 million, up 14.7% from the year-ago quarter.

The S&P 500 Index continued its strong downward trend last week, reaching its lowest level since December 17 last year. It ended the week at $6,740, down substantially from the year-to-date high of $7,000. Let's explore some of the top catalysts for the SPY, IVV, and VOO ETFs this week.

US inflation report A key catalyst for the S&P 500 and its ETFs this week will be the upcoming US consumer inflation report on Wednesday.

This is a crucial report that forms the second part of the Federal Reserve’s dual role after the labor report. 

Data released on Friday showed that the economy shed over 92,000 jobs in February, that worst reading in years. The unemployment rate jumped to 4.4%, while wage growth remained steady.

Economists expect the upcoming US inflation report to show that the headline Consumer Price Index (CPI) rose to 2.5% in February, while the core CPI remained unchanged at 2.5%.

A higher inflation report than expected will make it hard for the Federal Reserve to cut interest rates as Donald Trump has suggested. The S&P 500 Index and other indices do well when the Fed is cutting interest rates.

US and Iran war The most important catalyst for the S&P 500 Index will be the ongoing war in Iran, which escalated during the weekend, with Israel bombing a key Iranian refinery. 

This war has led to a surge in energy prices in the United States and other countries. Brent, the global benchmark, has jumped from the year-to-date low of $55 to over $100. Similarly, the US oil benchmark has continued soaring aa traffic at the Strait of Hormuz fades.

The price of other energy products like natural gas and gasoline have continued rising this year, which will lead to a higher inflation rate in the US.

While energy companies in the S&P 500 Index are benefiting, other sectors, especially transportation and manufacturing, are all under substantial pressure as the war continues

Signs that the war is ending will be bullish for the S&P 500 and other US indices. A good example of this happened on Wednesday last week when the media reported that Iran had reached out to the United States for talks to end the war.

Top corporate earnings The other key catalyst for the S&P 500, SPY, IVV, and VOO ETFs is the upcoming corporate earnings in the United States. 

While the earnings season has largely ended, some important companies will release their numbers this week.

Hewlett-Packard Enterprise and Casey’s General Stores will release their numbers on Monday. Oracle, a top player in the AI industry, will release its results on Tuesday.

Adobe’s results on Thursday will be important as they will demonstrate whether artificial intelligence tools by companies like OpenAI and Anthropic are disrupting its business.

The other top corporate earnings to watch will be Dollar General, Ulta Beauty, Lennar Corporation, UiPath, and Campbell’s Soup.

S&P 500 Index rising wedge pattern  The other key catalyst for the S&P 500 Index is its technicals, which point to further downside in the near term. 

As the chart above shows, the index has formed a rising wedge pattern, which is made up of two ascending and converging trendlines. It has already moved below the lower side of this pattern and the Strong, Pivot, and Reverse level of the Murrey Math Lines tool.

Therefore, the most likely scenario is where the index continues falling, potentially to the next key support level at $6,000.